Oxfendazole (OFZ) is efficacious for porcine cysticercosis at 30mg/kg. OFZ is not registered to be used at this dose. The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported. Forty-eight pigs allocated into two groups received OFZ (30mg/kg) orally as a commercial (CF) or as experimental formulation (SMF). Samples (blood, muscle, liver, kidney and fat) were collected over 30days post-treatment and analyzed by HPLC. OFZ was the main compound recovered in plasma, followed by FBZSO2 and low FBZ concentrations. OFZ AUC0-LOQ (209.9±33.9μg·h/ml) and Cmax (5.40±0.65μg/ml) parameters for the CF tended to be higher than those for the SMF (AUC0-LOQ: 159.4±18.3μgh/ml, Cmax: 3.80±0.35μg/ml). The highest total residue (OFZ+FBZSO2+FBZ) concentrations were quantified in liver, followed by kidney, muscle and fat tissue. FBZSO2 residue levels were the highest found in muscle (0.68±0.39μg/g) and fat (0.69±0.39μg/g). In liver and kidney the highest residues corresponded to FBZ (5.29±4.36μg/g) and OFZ (2.86±0.75μg/g), respectively. A withdrawal time of 17days post-treatment was established before tissues are delivered for human consumption.
Bibliographical noteFunding Information:
Funding: This work was funded by the Bill and Melinda Gates Foundation through grants number 1016506 and 23981 and also funds from the Department for International Development (DFID) UK. HG is a Wellcome Trust Senior Research Fellow in Public Health. The funders had no role in study design; data collection, analysis, or interpretation; in writing the report, or in the decision to submit the article for publication.
- Tissue residues
- Withdrawal time